Innoviva (INVA) Other financing activities (2014 - 2025)

Innoviva's (INVA) quarterly Other financing activities came in at $10.7 million in Q3 2025, up 46421.74% on a QoQ basis from $23000.0 in Q4 2017.

Innoviva (INVA) Other financing activities (2014 - 2025) Analysis & Trends

Innoviva (INVA) has 4 years of Other financing activities data on file, last reported at $10.7 million in Q3 2025.

Quarterly Other financing activities changed N/A year-over-year to $10.7 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $10.7 million (up 3013.86% YoY) and the FY2025 annual result came in at $10.7 million, changed N/A from the prior year.
Other financing activities improved to $10.7 million in Q3 2025, from $23000.0 in the prior quarter.
In the past five years, Other financing activities ranged from a high of $10.7 million in Q3 2025 to a low of $10.7 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Innoviva	1.54 Bn	968.79 Mn	90.62 Mn

Download Data